Close Menu

Jane Pine Wood

Sep 15, 2016

OPKO Health has appointed Jane Pine Wood as chief legal and compliance officer of its wholly owned subsidiary, BioReference Laboratories. Wood comes to OPKO Health from the multistate law firm McDonald Hopkins, where she served as a member of the firm's board of directors. She specializes in laboratory regulatory and compliance matters, and has counseled more than 500 pathology groups and 350 clinical laboratories. Wood is also a frequent speaker at national and state laboratory and pathology meetings and a contributor to association publications.

More Like This

Oct 30, 2020

DotLab Scientific Advisory Board

DotLab, a women's health company developing a microRNA-based test for endometriosis, has formed its scientific advisory board. Appointees include Kristof Chwalisz, therapeutic area head urology, gynecology at Abbott Laboratories; Anula Jayasuriya, founder and managing director at EXXclaim Capital; Thomas Musci, former chief medical officer at Ariosa Diagnostics (acquired by Roche) and former faculty member at the University of California, San Francisco; Harold Sauer, chairman of the department of obstetrics and gynecology at Bridgeport Hospital, part of the Yale New Haven Health System; Eric Surrey, medical director at the Colorado Center for Reproductive Medicine; and Robert Taylor, professor of obstetrics and gynecology and assistant dean and director of the Md-PhD program at the University at Buffalo.

Oct 29, 2020

CareDx: Peter Maag, Reginald Seeto

CareDx announced that current Chairman and CEO Peter Maag will assume the role of executive chairman of the board, effective Nov. 1, and that current President and Chief Business Officer (CBO) Reginald Seeto will then assume the role of president and CEO. Seeto will also join the company's board.

Maag joined CareDx in 2012 as CEO and led the company through its IPO. Seeto joined CareDx in 2018 as president and CBO, leading the company's commercial, clinical, manufacturing, and R&D organizations. 

Oct 29, 2020

Prime Genomics: Robert Weigle

Prime Genomics, a company developing noninvasive testing to improve breast cancer detection, has named Robert Weigle as CEO. Weigle joins the firm from DigitalDx Ventures where he was an entrepreneur in residence. He has previously held senior-level sales and marketing positions at Johnson & Johnson, Baxter, and several startup ventures.

Oct 29, 2020

Qiagen: Jean-Pascal Viola

Qiagen has appointed Jean-Pascal Viola as senior vice president, head of the molecular diagnostics business area, in addition to his current role as leader of corporate business development and intellectual property and litigation, which he assumed in 2015. Viola will also continue to serve as a member of Qiagen's executive committee. He joined Qiagen in 2005 and has held various roles in Singapore, the US, and Germany. Since joining the business development team in 2007, he played a leading role in the acquisitions of Cellestis, Stat-Dx, NeuMoDx, and the assets of Forumlatrix related to digital PCR.

Oct 29, 2020

Clear Labs: Jeff Field

Clear Labs has hired Jeff Field to be its chief commercial officer. He has more than two decades of experience in healthcare and formerly was CCO at IDbyDNA and VP of oncology at Foundation Medicine. At Clear Labs, Field will oversee the continued commercialization of the company's tests including Clear Safety and Clear Dx nationally and internationally.

Oct 23, 2020

Becton Dickinson: John DeFord, Patrick Kaltenbach, Dave Hickey

Becton Dickinson announced the retirement of Chief Technology Officer John DeFord, who joined BD with the acquisition of CR Bard in 2017. DeFord will be succeeded by Patrick Kaltenbach, who will serve as CTO and executive vice president. Kaltenbach joined BD as president of the life sciences segment in May 2018 after having most recently served as Agilent's senior vice president and president of that firm's life sciences and applied markets group. Dave Hickey, who currently serves as BD's worldwide president of integrated diagnostics solutions, will be promoted to the position of executive vice president and president of life sciences. The new appointments will be effective Jan. 1, 2021.

Oct 23, 2020

Biocept: Samuel Riccitelli

Biocept has appointed Samuel Riccitelli to its board of directors, effective immediately, and ahead of the planned retirement of Bruce Huebner, who will leave the board on Nov. 30, 2020Riccitelli boasts 35 years of experience in the molecular diagnostics industry, having served in executive-level positions and on the boards of multiple publicly traded companies. At Biocept, he will initially serve on the audit committee and the science and technology committee.

Riccitelli currently serves as an independent consultant to healthcare companies and is a director of OrthoPediatrics, a company focused on the orthopedic implant needs of children. Prior to that he was CEO of Pathnostics, a molecular diagnostics company focused on improving antibiotic stewardship. He also served as chairman of Precipio; president, CEO, and director of Signal Genetics; and executive VP and chief operating officer of Genoptix. Riccitelli received a BA from Washington and Jefferson College and an MS in engineering from The University of Texas.

Oct 22, 2020

Diadem: Paul Kinnon

University of Brescia spinout Diadem has appointed Paul Kinnon its CEO. Kinnon was previously CEO of PredictImmune, Transgenomic, and Zygem. He has also held executive positions at Life Technologies, now part of Thermo Fisher Scientific, Guava Technologies, and Cellomics. Founded in 2012, Diadem is developing a blood-based test to predict early onset Alzheimer's disease. Its flagship test is AlzoSure, which measures conformational changes in the p-53 pathway by targeting unfolded p-53, which is overexpressed in Alzheimer's patients.

Oct 08, 2020

Caris Life Sciences: Brian Lamon

Caris Life Sciences has appointed Brian Lamon as its chief business officer and head of biopharma business development. Lamon brings over 15 years of experience from large pharma and academia to the firm. He previously worked for Bristol Myers Squibb as a VP and development lead. Prior to that, he held several leadership roles in clinical development and business development for the same company.

Before joining industry, Lamon was assistant dean of research development and an assistant professor in the department of pathology and laboratory medicine at Weill Medical College of Cornell University in New York. He remains active on the faculty through a courtesy appointment as assistant professor.

Oct 08, 2020

Proscia: Monica Santamaria-Fries

Proscia announced Monica Santamaria-Fries has joined the company as digital transformation officer. She has been with The Permanente Medical Group (TPMG) for more than 30 years, including as chief of pathology at the Kaiser Foundation Hospital in Santa Clara, California. She also was clinical lab director and assistant chair for the Regional TPMG Pathology Department.

Oct 07, 2020

Nobel Prize: Emmanuelle Charpentier, Jennifer Doudna

Emmanuelle Charpentier and Jennifer Doudna have been jointly awarded the 2020 Nobel Prize in chemistry for their discovery and development of the CRISPR/Cas9 genome editing method.

"There is enormous power in this genetic tool, which affects us all. It has not only revolutionized basic science, but also resulted in innovative crops and will lead to ground-breaking new medical treatments," said Nobel Committee for Chemistry Chair Claes Gustafsson in a statement.

Charpentier is the director of the Max Planck Unit for the Science of Pathogens in Berlin. She holds a PhD from the Institute Pasteur in France.

Doudna is a professor at the University of California, Berkeley, and a Howard Hughes Medical Institute investigator. She holds a PhD from Harvard Medical School.

The two Nobel laureates will equally share the 10 million Swedish kronor ($1.12 million) award.

Oct 06, 2020

Pillar Biosciences: Robert Forrester

Pillar Biosciences, a next-generation sequencing cancer diagnostics company, has added Robert Forrester as an independent board member. Forrester has previously served as CEO of Verastem Oncology, COO of Forma Therapeutics, CEO and CFO of CombinatoRx, and CFO of Coley Pharmaceutical. He is also cofounder and chief experience officer of EQRx, which makes innovative medicines at dramatically lower prices for the benefit of society. Forrester has also served as managing director of the Proprietary Investment Group at MeesPierson.

Oct 06, 2020

Helio Health: Wei Li

Helio Health has appointed Wei Li to its advisory board. Li has more than 20 years of experience in bioinformatics research and development and is currently the endowed chair and professor of bioinformatics for the biological chemistry department at the University of California, Irvine's School of Medicine. He previously was the Dan L. Duncan Chair professor in the division of biostatistics at the Dan L. Duncan Cancer Center as part of the molecular and cellular biology department at the Baylor College of Medicine.

Oct 06, 2020

Karius: Alexander Ford

Karius has appointed Alexander (Alec) Ford as CEO. Ford most recently served as chief operating officer of Myriad Genetics. He will replace current CEO Mickey Kertesz, who will transition to the roles of president and chief product officer.

Oct 05, 2020

Myriad Genetics: Alexander Ford

Myriad Genetics said in a filing with the US Securities and Exchange Commission that Alexander Ford has resigned as chief operating officer as of Oct. 2. Before recently becoming chief operating officer, he was president of Myriad's women's health division and president of Myriad Genetic Laboratories. Prior to joining Myriad in 2010, Ford worked in various leadership roles in sales, business development, and product marketing at Novartis, Sanofi Aventis, Nektar Therapeutics, and Pfizer.